Page 28 - CIBEREHD2016-ENG

Biobank: Biobanc Clínic and Collection
of Steatotic Livers
Biobank of the Hospital Clinic de Barcelona (Biobanc Clinic)
The CIBEREHD has set up a platform which collects, stores and distributes biological samples connected with digestive diseases, and supported by the infrastructure of the IDIBAPS Biobank.
The work done by the CIBEREHD Biobank Platform includes two types of collections: gastrointestinal and pancreatic oncology (OGP) and inflammatory intestinal diseases (IID). The samples are deposited at the HCB-IDIBAPS Biobank.
GASTROINTESTINAL AND PANCREATIC ONCOLOGY (OGP). The Biobank has samples of plasma, serum, DNA and peripheral blood mononuclear cells (PBMC) from the following donors:
• Colorectal cancer: 283 donors.
• Patient with intermediate risk of colorectal cancer: 6296 donors.
• Patient or relative with high risk of colorectal cancer (polyposic or non-polyposic syndrome): 760 donors.
• Patient or relative with a moderate risk of colorectal cancer (familial colorectal cancer): 65 donors.
• Pancreas cancer: 7 donors.
• Intraductal papillary mucinous tumour or mucinous cystic tumour: 22 donors.
• Chronic pancreatitis: 25 donors.
• Gastric cancer: 10 donors.
904 new donors were received only from the Hospital Clínico de Barcelona in 2016 and work has been done on improving the circuit for management of the samples in order to speed up their processing, as well as registration of the consents covering the samples.
Similarly, a total number of 1142 different aliquots were assigned in the following projects:
• Tackling key aspects in the virotherapy of cancer with adenovirus: arrival of systemic viruses in tumours, replication, dissemination and immunity. Cristina Fillat, assignment of 51 serums.
• Designing and adjusting kits for diagnosis of colon cancer in the blood based on multiplex platforms (COLONTEST Project). Antoni Castells, assignment of 233 plasmas.
• Identification of new biomarkers for prevention of colorectal cancer. Antoni Castells, assignment of 528 serums.
• Metabolomics-based detection of early stage cancers. Antoni Castells and UniversalDx, assignment of 330 serums.
INFLAMMATORY INTESTINAL DISEASES (IID). The Biobank mainly has samples of DNA (in some cases, also plasma and PBMC) from the following donors:
• Crohn’s disease: 2086 donors.
• Ulcerous colitis: 1643 donors.
• Indeterminate colitis: 29 donors.
• Lymphocytic colitis: 67 donors.
• Collagenous colitis: 77 donors.
In this period 347 new donors were received, 186 of whom (53.6%) are Catalonia health centres other than the Hospital Clínic de Barcelona, and 89 of whom (25.6%) are from health centres outside Catalonia.
A great effort has also been made to improve the management of collection of IID along with the Grupo Español de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa (GETECCU). This effort has resulted in drafting an agreement for establishing the IID bank, an improvement in the coordination of the shipments of samples collected nationwide, as well as proper administration of the information associated with the
12283